Generex Biotechnology Vaccine Strategy Presented at International Conference in London
WORCESTER, MA - May 24, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT) announced today that Dr. Douglas Powell, Director of Immunobiology at its wholly-owned Antigen Express subsidiary, has presented Antigen's vaccine development strategy at an international conference in London, UK. The international meeting, "Developing New Anti-Infective Agents - Challenges and Opportunities" (www.anti-infectives-forum.com), is being held May 24th and 25th and brings together leading individuals from academia, industry, and regulatory agencies.
The focus of Dr. Powell's presentation was the immunogenicity of proprietary peptide vaccines being developed by Antigen Express, both when used alone and in combination with other types of vaccines. The Company is currently conducting a Phase II clinical trial of one of its peptides in breast cancer patients and a Phase I trial in volunteers of other peptides for the potentially pandemic H5N1 avian influenza. In both of these disease areas, cancer and avian influenza, novel forms of immunotherapy and vaccine are clearly needed.
About Generex
Generex is engaged in the research and development of drug delivery
systems and technologies. Generex has developed a proprietary
platform technology for the delivery of drugs into the human body
through the oral cavity (with no deposit in the lungs). The
Company's proprietary liquid formulations allow drugs typically
administered by injection to be absorbed into the body by the
lining of the inner mouth using the Company's proprietary
RapidMistT device. The Company's flagship product, oral insulin
(Generex Oral-lynT), which is available for sale in Ecuador for the
treatment of patients with Type-1 and Type-2 diabetes, is in
various stages of clinical trials around the world. Antigen Express
is a wholly owned subsidiary of Generex. The core platform
technologies of Antigen Express comprise immunotherapeutics for the
treatment of malignant, infectious, allergic, and autoimmune
diseases. For more information, visit the Generex website at
www.generex.com or the Antigen
Express website at www.antigenexpress.com.
Safe Harbor Statement: This release and oral statements made from
time to time by Generex representatives concerning the same subject
matter may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements can be identified by introductory words such as
"expects," "plans," "intends," "believes," "will," "estimates,"
"forecasts," "projects" or words of similar meaning, and by the
fact that they do not relate strictly to historical or current
facts. Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions
and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex cannot be sure when or
if it will be permitted by regulatory agencies to undertake
additional clinical trials or to commence any particular phase of
clinical trials. Because of this, statements regarding the expected
timing of clinical trials cannot be regarded as actual predictions
of when Generex will obtain regulatory approval for any "phase" of
clinical trials. Generex claims the protection of the safe harbor
for forward-looking statements that is contained in the Private
Securities Litigation Reform Act.
# # #
For more information, please contact:
For Generex:
Shayne Gilliatt of Generex
800-391-6755 or 416-364-2551
Andrew Hellman of CEOcast, Inc.
212-732-4300
Posted: May 2007
